Stay updated on Pembrolizumab-Ibrutinib Combo in CRC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab-Ibrutinib Combo in CRC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab-Ibrutinib Combo in CRC Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    7 days ago
    Change Detected
    Summary
    The clinical trial record for pembrolizumab combined with ibrutinib is displayed, including the study design, eligibility criteria, outcomes, and record history. The record also links to its study protocol and statistical analysis plan.
    Difference
    49%
    Check dated 2026-11-07T14:32:36.000Z thumbnail image
  3. Check
    14 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.2 to v3.8.0 while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-31T15:25:54.000Z thumbnail image
  4. Check
    21 days ago
    Change Detected
    Summary
    A sitewide banner announces NIH’s terminology transition from “Artificial Intelligence” to “Super Intelligence.” The study record continues to display a 403 error.
    Difference
    1%
    Check dated 2026-10-24T18:22:53.000Z thumbnail image
  5. Check
    28 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.1 to v3.7.2 while the page continued to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-17T21:56:47.000Z thumbnail image
  6. Check
    35 days ago
    Change Detected
    Summary
    The footer revision changes from v3.7.0 to v3.7.1 while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-10T22:04:27.000Z thumbnail image
  7. Check
    56 days ago
    Change Detected
    Summary
    Access to the study record for NCT03332498 now displays a 403 Forbidden error page, replacing the previous content that described the study. This indicates the page is currently blocked or unavailable, preventing viewing the study details on ClinicalTrials.gov.
    Difference
    18%
    Check dated 2026-09-19T20:52:28.000Z thumbnail image

Stay in the know with updates to Pembrolizumab-Ibrutinib Combo in CRC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab-Ibrutinib Combo in CRC Clinical Trial page.